The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
While Semaglutide GLP-1 appears to be more effective for individuals with a higher BMI, the decision between the two medications is individualized based on factors such as patient preferences concerning injection schedules, insurance coverage, and tolerance to side effects
Until these questions are addressed, recommending or facilitating access to prohibited substances such as peptides with limited evidence in human subjects is not within best practice for evidence-based sports medicine providers
Family Owned Since 1968
The result is a deep sense of calm, clarity, and balance without sedation or numbing
Expression of gamma-glutamyltransferase 1 in glioblastoma cells confers resistance to cystine deprivation-induced ferroptosis
